

Supplementary table 1. Response to therapy for EBVaGC patients

	First line therapy, n=31	Second line therapy, n=12	Anti-PD1 therapy, n=7
CR	1 (3.2)	0 (0)	0 (0)
PR	8 (25.8)	3 (25.0)	2 (28.5)
SD	19 (61.3)	6 (50.0)	2 (28.5)
PD	3 (9.7)	3 (25.0)	3 (43.0)
ORR	7 (29.0)	3 (25.0)	2 (28.5)
DCR	28 (90.3)	9 (75.0)	4 (57.0)
mPFS	9.8 months	6.0 months	2.8 months

Data were present as n (%) unless specified.

EBVaGC: Epstein-Barr virus associated gastric cancer; PD-1: programmed death 1; CR: complete response; PR: partial response; SD: stable disease; PD: progression disease; ORR: objective response rate; DCR: disease control rate; mPFS: median progression-free survival.